Dermatologist-turned-entrepreneur Dr. Reid Waldman is leading one of Connecticut’s most closely watched biopharmaceutical startups.
As co-founder and CEO of New Haven-based Veradermics Inc., Waldman has built a fast-growing company developing new treatments for skin conditions. In October 2025, Veradermics closed an oversubscribed $150 million Series C funding round led by SR One, with participation from several new and existing investors.
The latest fundraise more than doubles the company’s total funding since its 2019 founding by Waldman and fellow dermatologist Dr. Tim Durso. Proceeds will support ongoing trials for VDPHL01, an investigational oral therapy for androgenetic alopecia — or pattern hair loss — which affects nearly 80 million Americans.
Veradermics recently reported positive preliminary results from its Phase 2 study and plans to advance to pivotal Phase 3 trials.
Waldman, a board-certified dermatologist with more than a decade of clinical experience, has authored over 100 publications, including the textbook “Dermatology for the Primary Care Provider.”